Two ASX-listed ventures are among the companies now investing billions of dollars to develop an emerging immunotherapy treatment known as CAR-T. From the upcoming Innovation issue, out on February 26.
Biotech entrepreneur Paul Hopper at KPD Australia. His latest venture, Chimeric, has begun a phase-one clinical trial of its CAR-T therapy in the US. Louie Douvis
Laurie Adami was 45 when she began “feeling crummy”, exhausted and plagued with constant sinus infections.
It was 2006 and the high-flying tech executive, who was juggling her career while raising a young son, was told by doctors her blood tests looked normal. Given she was a busy working mum, they opined, it was hardly surprising she was tired at the end of the day.
Fetching latest articles
Original URL: https://www.afr.com/technology/cancer-free-after-12-years-why-you-re-hearing-the-c-word-more-often-20201217-p56ohe
